# Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT02244489** · PHASE1 · TERMINATED · sponsor: **Sierra Oncology LLC - a GSK company** · enrollment: 16 (actual)

## Conditions studied

- Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Momelotinib (MMB)
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02244489
- **Lead sponsor:** Sierra Oncology LLC - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-05
- **Primary completion:** 2017-03-08
- **Final completion:** 2017-04-05
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244489, "Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02244489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*